Kimyrsa Now Offered for Severe Bacterial Skin/Skin Structure Infections

Kimyrsa ™ (oritavancin) is now readily available for the treatment of grownups with severe bacterial skin and skin structure infections (ABSSSI) triggered by vulnerable isolates of designated Gram-positive bacteria.

Kimyrsa is a single-dose, long-acting lipoglycopeptide antibiotic shown for the treatment of ABSSSI triggered by vulnerable isolates of the following Gram-positive bacteria: Staphylococcus aureus (consisting of methicillin-susceptible [MSSA] and -resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (consists of S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates just).

The effectiveness and security of Kimyrsa was supported by information from the stage 3 SOLO I (ClinicalTrials.gov Identifier: NCT01252719) and II (ClinialTrials.gov Identifier: NCT01252732) trials, which compared a single dosage of oritavancin 1200mg intravenously to vancomycin (1g or 15mg/kg two times day-to-day intravenously for 7 to 10 days).

Findings from both research studies revealed that oritavancin was as efficient as vancomycin for the main and secondary endpoints. Approval was likewise based upon information from a pharmacokinetics (PK) research study that compared Kimyrsa (n= 50) administered over 1 hour to Orbactiv (oritavancin) (n= 52) administered over 3 hours for the treatment of grownups with ABSSSI.

Continue Reading

The most typical unfavorable responses reported with oritavancin items consist of headache, queasiness, throwing up, limb and subcutaneous abscesses, and diarrhea. In the PK research study, hypersensitivity, pruritus, chills and pyrexia happened in 2 or more clients getting Kimyrsa.

Kimyrsa is provided as a lyophilized powder in a single-dose vial consisting of 1200mg of oritavancin. As there are 2 oritavancin items readily available (Kimyrsa and Orbactiv), the advised dose and dosage preparation guidelines for Kimyrsa ought to be thoroughly followed.

Recommendations

1. Melinta Therapies reveals industrial accessibility of Kimyrsa ™ (oritavancin).[press release] Morristown, NJ: July 7, 2021.
2. Kimyrsa[package insert] Lincolnshire, IL: Melinta Therapies, LLC; 2021.

This short article initially appeared on MPR